DOP039: Exploring stoma rates in Crohn’s Disease in the biologic era: A population-based time trend analysisECCO'18 Vienna 2018
1
DOP041: Surgery and hospitalisation in patients with Inflammatory Bowel Disease; 10 years follow-up of a Danish population-based inception cohortECCO'18 Vienna 2018
1
DOP042: Need for ileocaecal resections, but not ileo-colic re-resections, has decreased – a nationwide study of temporal trends in Crohn surgery in Sweden 1990-2014ECCO'18 Vienna 2018
1
DOP043: Comparative outcomes of ileal pouch revision vs. excision for pouch failure within the American College of Surgeon National Surgical Quality Improvement ProgrammeECCO'18 Vienna 2018
1
DOP048: Vedolizumab levels during induction are associated with long-term clinical and endoscopic remission in patients with Inflammatory Bowel DiseaseECCO'18 Vienna 2018
1
DOP049: Combination therapy of cyclosporine and vedolizumab is effective and safe for severe, steroid-resistant Ulcerative Colitis patients: A prospective studyECCO'18 Vienna 2018
1
DOP050: Influence of disease location on vedolizumab efficacy in Inflammatory Bowel Disease: A real-life multicentre experienceECCO'18 Vienna 2018
1
DOP051: Shorter disease duration is associated with higher response rates to vedolizumab in Crohn’s Disease but not Ulcerative Colitis: A multi-centre consortium analysisECCO'18 Vienna 2018
1
DOP052: Vedolizumab versus ustekinumab for Crohn's Disease: Comparative effectiveness in a real-life observational cohort study (ICC Case Series)ECCO'18 Vienna 2018
1
DOP053: Impact of concomitant immunomodulator use on vedolizumab effectiveness: A multicentre consortium propensity score–matched analysisECCO'18 Vienna 2018
1
DOP054: Vedolizumab in combination with steroids for induction therapy in Crohn’s Disease: An exploratory analysis of the GEMINI 2 and GEMINI 3 studiesECCO'18 Vienna 2018
1
DOP055: Luminal application of a GATA3-specific DNAzyme ameliorates mucosal inflammation in a randomised trial with active Ulcerative Colitis patientsECCO'18 Vienna 2018
1
DOP058: Combined stem cells and anticytokine therapy contributes to a more pronounced decrease in the degree of inflammation of the intestinal mucosa in Crohn's DiseaseECCO'18 Vienna 2018
1
DOP059: Combined anticytokine and local mesenchymal stem cells therapy promotes longer healing of simple fistulas in patients with Crohn's DiseaseECCO'18 Vienna 2018
1